Holen Sie sich die Stockscreener-App
132.48
0.67%
0.88
Handel nachbörslich:
133.51
1.03
+0.78%
Neurocrine Biosciences Inc Aktie (NBIX) Neueste Nachrichten
Neurocrine’s $2.9B Soleno Buyout Brings What Could Become It’s Next Blockbuster Drug - MedCity News
Five More Things To Know About Neurocrine’s $2.9bn Bid For Soleno - Citeline News & Insights
This Bay Area company's stock fell to less than $1, but one decision led it to a $53-a-share acquisition - The Business Journals
Neurocrine to seek all Soleno shares in tender offer (NASDAQ: SLNO) - Stock Titan
Why Soleno Therapeutics Stock Rocketed Higher on Monday - The Motley Fool
Key facts: Neurocrine buys VYKAT XR for $2.9B; adds rare‑disease asset - TradingView
Neurocrine Agrees $2.9 Billion Soleno Deal At 34% Premium - GuruFocus
Oppenheimer Adjusts Neurocrine Biosciences Price Target to $220 From $192, Maintains Outperform Rating - marketscreener.com
Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9B to Expand Rare Disease Portfolio - Oncodaily
Soleno Stock Soars on $2.9 Billion Neurocrine Buyout. Its Hunger Drug Is a Different Weight-Loss Play. - Barron's
Baird reiterates Neurocrine Bio stock rating on acquisition potential - investing.com
Baird reiterates Neurocrine Bio stock rating on acquisition potential By Investing.com - Investing.com Australia
Cooley, Wilson Sonsini Steer Neurocrine's $2.9B Soleno Buy - Law360
Neurocrine Biosciences to Acquire Soleno Therapeutics for $2.9B - National Today
American Neurocrine Biosciences acquires Soleno Therapeutics for $2.9 billion - AKM.RU
Soleno Therapeutics Soars as Neurocrine Unveils $2.9B All-Cash Buyout at $53 a Share - Yahoo Finance
Neurocrine Biosciences' (NBIX) "Buy" Rating Reaffirmed at Needham & Company LLC - marketbeat.com
Neurocrine Biosciences Details $2.9B Soleno Buyout, Touts Vykat XR as Potential Blockbuster - Yahoo Finance
Vykat caveat: Neurocrine’s $2.9B Soleno bid low-ball? - BioWorld MedTech
Neurocrine Biosciences, Inc. entered into a definitive agreement to acquire Soleno Therapeutics, Inc. from Anish Bhatnagar, James Mackaness, and others for $2.8 billion. - marketscreener.com
Neurocrine Is Making a $2.9 Billion Bet on a New Kind of Drug - inc.com
Soleno Therapeutics shares jump nearly 40% on $2.9 billion takeout deal - MSN
Neurocrine Biosciences Acquires Soleno Therapeutics for $2.9 Billion, Expands Rare Disease Portfolio With FDA-Approved VYKAT XR for Prader-Willi Syndrome 1 - Minichart
UBS reiterates Neurocrine Bio stock rating on acquisition news By Investing.com - Investing.com South Africa
Neurocrine to Buy Soleno, Nabbing Drug for Relentless Hunger Disorder - WSJ
Soleno Therapeutics Stock Skyrockets 33% After Neurocrine Biosciences Announces Acquisition Deal - TIKR.com
Neurocrine-Soleno Deal Garners Wall Street Praise — Analyst Applauds Business Development Acumen - Stocktwits
UBS reiterates Neurocrine Bio stock rating on acquisition news - investing.com
Neurocrine to acquire Prader-Will drug in $2.9B Soleno buyout - BioPharma Dive
Neurocrine Biosciences to buy Soleno Therapeutics in $2.9B deal - Axios
Quarterly Trades: Is Neurocrine Biosciences Inc stock technically oversold2026 Decliners & Risk Managed Investment Signals - baoquankhu1.vn
Neurocrine expands into metabolic diseases with $2.9 billion Soleno buyout - Reuters
Neurocrine to Buy Soleno Therapeutics for $2.9 Billion - Bloomberg.com
Neurocrine Biosciences to acquire Soleno Therapeutics in $2.9B deal - Yahoo! Finance Canada
Neurocrine Biosciences to acquire Soleno Therapeutics for $2.9 billion - MLex
Neurocrine Biosciences to Acquire Soleno Therapeutics in $2.9 Billion Deal - marketscreener.com
Soleno Therapeutics (SLNO) Stock Jumps 30% on Neurocrine $2.5B Buyout Report - MEXC
Neurocrine Biosciences Agrees to Acquire Soleno Therapeutics for $2.9B - contractpharma.com
Neurocrine Buys Soleno To Tap High-Growth Rare Disease MarketNeurocrine Biosciences (NASDAQ:NBIX), Sol - Benzinga
According to the latest disclosed agreement terms, if the acquisition is terminated under specific circumstances, Soleno Therapeutics (SLNO) will be required to pay Neurocrine Biosciences (NBIX) a termination fee of up to 953 millions dollars. - Bitget
Neurocrine to Acquire Soleno, Expanding Rare Disease Portfolio - TipRanks
Neurocrine Biosciences to Acquire Soleno Therapeutics for $2.9 Billion in Cash - marketscreener.com
Soleno to Be Acquired by Neurocrine in $53-Per-Share Tender Offer - TradingView
Neurocrine Biosciences (NBIX) agrees to buy Soleno (SLNO) for $53/share - Stock Titan
Neurocrine to buy Soleno (NASDAQ: SLNO) in $2.9B all-cash deal - Stock Titan
Neurocrine Biosciences to Acquire Soleno Therapeutics in $53-Per-Share Tender Offer and Merger - TradingView
Neurocrine Biosciences Inc if deal terminated under some circumstances Soleno will pay co termination fee of $95.3 million - marketscreener.com
Neurocrine Biosciences Inc If Deal Terminated Under Some Circumstances Soleno Will Pay Co Termination Fee Of $95.3 Million - TradingView
Neurocrine (NBIX) to acquire Soleno in $2.9B rare-disease portfolio deal - Stock Titan
Neurocrine Biosciences : Presentation (FINAL NBIX SLNO Investor Presentation 0466 Final) - marketscreener.com
This Pharma Stock Is Surging 40%. Neurocrine Is Buying It in $2.9 Billion Deal. - Barron's
Neurocrine to buy Soleno Therapeutics for $2.9B - Breakingthenews.net
Neurocrine to buy Soleno Therapeutics for $2.9 billion - Yahoo! Finance Canada
Soleno Therapeutics rallies on report of $2.5B Neurocrine buyout talks - MSN
Neurocrine to acquire Soleno Therapeutics for $2.9 billion - Investing.com
Neurocrine wants to develop new obesity drugs. It’s reportedly nearing an acquisition to accelerate that move. - MarketWatch
Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio - ChartMill
Neurocrine nears over $2.5B deal to acquire Soleno Therapeutics, FT reports - TipRanks
Neurocrine nears $2.5B-plus deal to buy Soleno TherapeuticsFT (NBIX:NASDAQ) - Seeking Alpha
Neurocrine nears $2.5bn-plus deal for biotech behind obesity disorder treatment - ft.com
Neurocrine bets nearly $3bn on deal for insatiable hunger treatment - Financial Times
Nisa Investment Advisors Reduces Neurocrine Biosciences Stake - National Today
Nisa Investment Advisors LLC Sells 21,945 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Risks Report: Is Neurocrine Biosciences Inc a turnaround storyMarket Weekly Review & High Win Rate Trade Tips - baoquankhu1.vn
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) Q4 2025 earnings call transcript - MSN
0.10%
1.13%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):